ReviewCancers2020
Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disorders after Hematopoietic Stem Cell Transplantation: Pathogenesis, Risk Factors and Clinical Outcomes.
Review in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Real-world safety and efficacy of blinatumomab for EBV viremia and EBV-related PTLD after allogeneic hematopoietic stem cell transplantation.Bone marrow transplantation · 2026Article
- Kidney disease and transplantation in childhood cancer survivors.Pediatric nephrology (Berlin, Germany) · 2026Review
- Epidemiological Trends and Clinical Characteristics of Epstein-Barr Virus Infection in Febrile Children in Zhejiang, China: A Retrospective Study.Immunity, inflammation and disease · 2026Article
- Two birds, one BiTE: blinatumomab achieves concurrent B-ALL control and EBV clearance in post-HSCT patients: two cases report.BMC pediatrics · 2026Article
- Early Posttransplant Lymphoproliferative Disorder and Cryptosporidiosis After Liver Transplantation.Case reports in medicine · 2026Article
- Ocular post-transplant lymphoproliferative disorder after keratoplasty.American journal of ophthalmology case reports · 2025Article
- Epstein-Barr virus reactivation after haplo-peripheral blood stem cell transplantation in patients with hematological malignancies: immune reconstitution and influence on survival.Therapeutic advances in hematology · 2025Article
- Epstein-Barr virus positive post-transplant lymphoproliferative disorder with significantly decreased T-cell chimerism early after transplantation: A case report.World journal of radiology · 2024Article
- Elucidating the nexus between onco-immunology and kidney transplantation: An insight from precision medicine perspective.Heliyon · 2024Review
- Posttransplant Lymphoproliferative Disorder in a Patient With Alpha-1 Antitrypsin Deficiency: A Case Report.Cureus · 2024Article
- Outcomes for patients with EBV-positive PTLD post-allogeneic HCT after failure of rituximab-containing therapy.Bone marrow transplantation · 2024Article
- Metachronous spinal cord involvement B cell and subcutaneous tissue involvement NK/T cell lymphoid proliferations and lymphomas arising in post-transplantation mimicking general NK/T cell lymphoma: a case report and review of the literature.Frontiers in immunology · 2024Review
- Applying Rituximab During the Conditioning Regimen Prevents Epstein-Barr Virus Infection Following Allogeneic Hematopoietic Stem Cell Transplant in a Children's Cohort: A Retrospective Case-Control Study.Infectious diseases and therapy · 2023Article
- Spotlight on the impact of viral infections on Hematopoietic Stem Cells (HSCs) with a focus on COVID-19 effects.Cell communication and signaling : CCS · 2023Review
- LMP1 mediates tumorigenesis through persistent epigenetic modifications and PGC1β upregulation.Oncology reports · 2023Article
- Reinforcement of cell-mediated immunity driven by tumor-associated Epstein-Barr virus (EBV)-specific T cells during targeted B-cell therapy with rituximab.Frontiers in immunology · 2023Article
- Epstein-Barr virus-related lymphoproliferative disorders in T-cell repleted haploidentical transplantation with post-transplant cyclophosphamide.International journal of hematology · 2022Article
- Association Between Cytomegalovirus and Epstein-Barr Virus Co-Reactivation and Hematopoietic Stem Cell Transplantation.Frontiers in cellular and infection microbiology · 2022Article
- Review
- Epstein-Barr virus induced post-transplant lymphoproliferative disorder presenting with unilateral retinal involvement.American journal of ophthalmology case reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epstein-Barr virus (EBV) is a ubiquitous virus belonging to the human -herpes virus subfamily. After primary infection, EBV maintains a life-long latent infection. A major concern is that EBV can cause a diverse range of neoplasms and autoimmune diseases. In addition, patients undergoing hematopoietic stem cell transplantation or solid organ transplantation can experience post-transplant lymphoproliferative disorders (PTLDs) due to dysfunction or suppression of host's immune system, or uncontrolled proliferation of EBV-infected cells. In recent years, the number of EBV-associated PTLD cases has increased. This review focuses on the current understandings of EBV-associated PTLD pathogenesis, as well as the risk factors and clinical outcomes for patients after allogeneic stem cell transplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.